191 related articles for article (PubMed ID: 12354174)
1. Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
Olsson AG; Schwartz GG; Jonasson L; Linderfalk C
Acta Physiol Scand; 2002 Oct; 176(2):147-50. PubMed ID: 12354174
[TBL] [Abstract][Full Text] [Related]
2. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T;
JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825
[TBL] [Abstract][Full Text] [Related]
3. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Kinlay S; Schwartz GG; Olsson AG; Rifai N; Leslie SJ; Sasiela WJ; Szarek M; Libby P; Ganz P;
Circulation; 2003 Sep; 108(13):1560-6. PubMed ID: 12975259
[TBL] [Abstract][Full Text] [Related]
4. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
[TBL] [Abstract][Full Text] [Related]
5. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
6. The collaborative atorvastatin diabetes study: preliminary results.
Owen OG
Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
[TBL] [Abstract][Full Text] [Related]
7. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J
Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
[TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
[TBL] [Abstract][Full Text] [Related]
9. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
11. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
13. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
[TBL] [Abstract][Full Text] [Related]
14. Differences between statins on clinical endpoints: a population-based cohort study.
Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
[TBL] [Abstract][Full Text] [Related]
16. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
Olsson AG; Schwartz GG; Szarek M; Sasiela WJ; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A
Eur Heart J; 2005 May; 26(9):890-6. PubMed ID: 15764620
[TBL] [Abstract][Full Text] [Related]
17. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
19. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.
Correia LC; Spósito AC; Lima JC; Magalhães LP; Passos LC; Rocha MS; D'Oliveira A; Esteves JP
Am J Cardiol; 2003 Aug; 92(3):298-301. PubMed ID: 12888137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
